Ozempic, Wegovy stocks wilt following Trump GLP-1 comments

GLP-1 drug manufacturers experienced a market downturn following former President Trump's announcement of plans to significantly reduce the price of treatments like Novo Nordisk's Ozempic, potentially to $150 per month from its current $1,000 list price. This news led to share declines for Novo Nordisk (-3.1%), Eli Lilly (-2%), and Viking Therapeutics (-3.4%). The initiative aligns with a broader 'most favored nation' policy aiming to lower U.S. drug prices to international levels, with ongoing CMS negotiations for Ozempic's Medicare price highlighting continued regulatory pressure on pharmaceutical profitability.

Analysis

Former President Trump's recent signal to drastically reduce GLP-1 drug prices, specifically targeting Novo Nordisk's Ozempic to $150 from its approximate $1,000 list price, immediately triggered a negative market reaction. Shares of Novo Nordisk, Eli Lilly, and Viking Therapeutics fell 3.1%, 2%, and 3.4% respectively, reflecting investor concern over potential revenue compression for these key players in the weight-loss and diabetes market.

This initiative aligns with a broader "most favored nation" policy, aiming to bring U.S. drug prices in line with international benchmarks. The policy's potential implementation, as evidenced by Pfizer's prior agreement to offer Medicaid "most-favored nation" pricing, signals increasing regulatory pressure on pharmaceutical companies to curb domestic drug costs.

The ongoing Centers for Medicare and Medicaid Services (CMS) negotiations with Novo Nordisk regarding Ozempic's Medicare price underscore the immediate and tangible threat to profitability. This regulatory scrutiny, driven by the drugs' current cost-prohibitive nature for many Americans, suggests a sustained headwind for GLP-1 manufacturers.

Key Decisions for Investors

• Investors should closely monitor the progression of "most favored nation" drug pricing policies and the specific outcomes of CMS negotiations, as these will directly impact the revenue and profitability outlook for GLP-1 manufacturers.
• Evaluate the long-term implications of potential price caps on the growth trajectories and R&D investments of companies like Novo Nordisk, Eli Lilly, and Viking Therapeutics, considering the significant market impact already observed.
• Consider adjusting positions in pharmaceutical companies with high exposure to GLP-1 drugs, factoring in increased regulatory risk and potential margin erosion.